Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 1.00 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29416829 | 1.00 | DPP4 (1.00) | DPP4DPP7DPP8 | |
| SCHEMBL220478 | 1.00 | DPP4 (1.00) | DPP4DPP7DPP8 | |
| Hydrochloric Acid SCHEMBL299895 | 0.99 | DPP4 (0.98) | DPP4DPP7DPP8 | |
| Hydrochloric Acid SCHEMBL356224 | 0.99 | DPP4 (0.98) | DPP4DPP7DPP8 | |
| Hydrochloric Acid SCHEMBL356225 | 0.99 | DPP4 (0.98) | DPP4DPP7DPP8 | |
| Hydrochloric Acid SCHEMBL1069089 | 0.93 | DPP4 (0.86) | DPP4DPP7DPP8 | |
| Hydrochloric Acid SCHEMBL1069087 | 0.93 | DPP4 (0.86) | DPP4DPP7DPP8 | |
| SCHEMBL4593663 | 0.92 | DPP4 (0.85) | DPP4DPP7DPP8 | |
| SCHEMBL665644 | 0.92 | DPP4 (0.85) | DPP4DPP7DPP8 | |
| SCHEMBL8245189 | 0.92 | DPP4 (0.85) | DPP4DPP7DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024216053-A1 | SMALL MOLECULE CONTROL OF MEMBRANE AND SECRETED PROTEINS VIA HUMAN PROTEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-10-17 | — | — | WO | claimed |
| EP-3565573-B1 | PAC1 RECEPTOR AGONISTS (MAXCAPS) AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-08-23 | — | — | EP | claimed |
| EP-3199203-B1 | SUBSTITUTED XANTHINE DERIVATIVES | CONCERT PHARMACEUTICALS INC (US) | 2020-02-05 | — | — | EP | claimed |
| US-9597347-B2 | Compositions for treating obesity and insulin resistance disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-03-21 | — | — | US | claimed |
| US-9517273-B2 | Methods of treatment using modified FGF-21 polypeptides comprising non-naturally occurring amino acids | AMBRX, INC. (US) | 2016-12-13 | — | — | US | claimed |
| US-20150133396-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-05-14 | — | — | US | claimed |
| EP-1675578-B9 | INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR THE TREATMENT OF THE NEURODEGENERATIVE DISEASES FBD AND FDD | PROBIODRUG AG (DE) | 2014-06-25 | — | — | EP | claimed |
| US-8470781-B2 | Use of effectors of glutaminyl and glutamate cyclases | PROBIODRUG AG (DE) | 2013-06-25 | — | — | US | claimed |
| EP-1675578-B1 | INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR THE TREATMENT OF THE NEURODEGENERATIVE DISEASES FBD AND FDD | PROBIODRUG AG (DE) | 2013-05-22 | — | — | EP | claimed |
| US-20120149639-A1 | USE OF A DPP-IV INHIBITOR TO REDUCE HYPOGLYCEMIC EVENTS | BALKAN BOERK (US) | 2012-06-14 | — | — | US | claimed |
| US-20050137142-A1 | Combinations useful for the treatment of neuronal disorders | PROBIODRUG AG | 2005-06-23 | — | — | US | claimed |
| WO-2005049027-A2 | COMBINATIONS USEFUL FOR THE TREATMENT OF NEURONAL DISORDERS | PROBIODRUG AG (DE) | 2005-06-02 | — | — | WO | claimed |
| WO-2004098591-A2 | INHIBITORS OF GLUTAMINYL CYCLASE AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | PROBIODRUG AG (DE) | 2004-11-18 | — | — | WO | claimed |
| US-20040224875-A1 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2004-11-11 | — | — | US | claimed |
| EP-0937040-B1 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | NOVARTIS AG (CH) | 2004-07-21 | — | — | EP | claimed |
| WO-2003051848-A2 | IMIDAZOLIDINEACETIC ACID DERIVATIVES | FERRING BV (NL) | 2003-06-26 | — | — | WO | claimed |
| US-6124305-A | TREATING NON-INSULIN DEPENDENT DIABETES MELLITUS | NOVARTIS AG (CH) | 2000-09-26 | — | — | US | claimed |
| US-6011155-A | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV | NOVARTIS AG (CH) | 2000-01-04 | — | — | US | claimed |
| EP-0937040-A2 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | Novartis AG (CH) | 1999-08-25 | — | — | EP | claimed |
| WO-1998019998-A2 | N-SUBSTITUTED 2-CYANOPYRROLIDINES | NOVARTIS AG (CH) | 1998-05-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133396-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | FABP4, GPR119, SIRT1 | DPP4 201/4885DPP7 283/4885DPP8 251/4885 |
| US-20040224875-A1 | Inhibitors of glutaminyl cyclase | GLS2, GLS, GLUL | DPP4 2056/4885DPP7 1896/4885DPP8 2739/4885 |
| US-20050137142-A1 | Combinations useful for the treatment of neuronal disorders | MME, DNPEP, DPP4 | DPP4 3/4885DPP7 19/4885DPP8 22/4885 |
| US-20120149639-A1 | USE OF A DPP-IV INHIBITOR TO REDUCE HYPOGLYCEMIC EVENTS | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.